Innovative Products for Pediatric Patients

In the Branded Pharmaceutical market, Tris is focused on developing innovative products in the Pediatric space, specializing initially in central nervous system (CNS) products, where our goal is to deliver meaningful patient benefits and develop strong intellectual property positions.

Starting with our initial branded product, DYANAVEL® XR (amphetamine), Tris’ strategy is to apply our proprietary drug delivery technology to develop drug candidates to meet unmet medical needs for the underserved pediatric population. Our strategic initiatives for growth include continuing our internal R&D focus on CNS products by building a strong pipeline. 

DYANAVEL XR is a central nervous system (CNS) stimulant prescription medicine used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). DYANAVEL XR may help increase attention and decrease impulsiveness and hyperactivity in people with ADHD.

It is not known if DYANAVEL XR is safe and effective in children under 6 years of age.


DYANAVEL XR is a federally controlled substance (CII) because it can be abused or lead to dependence. Keep DYANAVEL XR in a safe place to prevent misuse and abuse. Selling or giving away DYANAVEL XR may harm others, and is against the law.

Tell your physician if you, your child, or any family members have ever abused or been dependent on alcohol, prescription medicines, or street drugs.

Additional Important Safety Information is available via the links on the right.

Download our returned goods policy »


DXR-0343(1) 07/17

Approved Products

Please see Important Safety Information, including Boxed WARNING for abuse and dependence, and Full Prescribing Information, including Medication Guide.